CHInese Medicine NeuroAid Efficacy on Stroke Recovery

NCT ID: NCT00554723

Last Updated: 2014-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CHIMES is a double blind, placebo controlled, randomized, multicenter study to test the hypothesis that NeuroAid is superior to placebo in reducing neurological deficit and improving functional outcome in patients with cerebral infarction of an intermediate range of severity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Stroke is a major cause of death and disability. Previous clinical studies performed in China have shown that NeuroAiD increase stroke patients'recovery in terms of neurological disability and functional outcome{Chen et al,2009}and thus may be beneficial as part of a post-stroke rehabilitation programme.

In the CHIMES study,we seek to test the hypothesis that NeuroAiD is superior to a placebo in reducing neurological deficit and improving functional outcome in patients recruited within 72 h after the ischemic stroke with intermediate range of severity {6\<\_NIHSS\<\_14}.More details of the study protocol have recently been published {Venketasubramanian et al,2009}.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Infarction Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

NeuroAid

Group Type EXPERIMENTAL

NeuroAid

Intervention Type DRUG

4 capsules 3 times daily, for three months

B

NeuroAid matched Placebo

Group Type PLACEBO_COMPARATOR

NeuroAid matched Placebo

Intervention Type DRUG

NeuroAid matched Placebo, 4 capsules 3 times daily, for three months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NeuroAid

4 capsules 3 times daily, for three months

Intervention Type DRUG

NeuroAid matched Placebo

NeuroAid matched Placebo, 4 capsules 3 times daily, for three months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Danqi Piantan Jiaonang (In China)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is aged 18 years old and above (for Singapore 21 years and above as this is the legal age of consent)
* Subject is on anti-platelet therapy
* Subject is presented a pre-stroke Modified Rankin Scale inferior or equal to 1
* Female subject is eligible to participate in the trial if she is of non-childbearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post menopausal)
* Subject or his/her legally acceptable representative is willing to provide written informed consent
* Subject is presented with cerebral infarction with compatible imaging at Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI)
* Time window is less than 72 hours after symptoms onset
* Subject with cerebral infarction with intermediate severity range: 6 ≤ NIHSS ≤ 14

Exclusion Criteria

* Subjects deemed unstable by investigator after thrombolysis treatment
* Subject has evidence of intra-cerebral hemorrhage on brain CT scan or MRI
* Subject has a rapidly improving neurological deficit
* Subject has definite indication for full-dose or long-term anticoagulation therapy
* Subject has other significant non-ischemic brain lesion which could affect function disability
* Subject has co-existing systemic diseases: terminal cancer, renal failure (creatinine \> 200 μmol/L, if known), cirrhosis, severe dementia or psychosis
* Subject has participated in another clinical trial within the last three months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Medical Research Council (NMRC), Singapore

OTHER_GOV

Sponsor Role collaborator

CHIMES Society

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marie Germaine Bousser, MD

Role: STUDY_DIRECTOR

APHP Paris

Christopher Chen, MBBS

Role: PRINCIPAL_INVESTIGATOR

National University of Singapore

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Prince of Wales Hospital

Hong Kong, , Hong Kong

Site Status

Penang General Hospital

George Town, Pulau Pinang, Malaysia

Site Status

Visayas Community Medical Center

Cebu City, Cebu, Philippines

Site Status

Baguio General Hospital and Medical Center

Baguio City, , Philippines

Site Status

Chong Hua Hospital

Cebu, , Philippines

Site Status

Davao Medical Center

Davao City, , Philippines

Site Status

Brokenshire Hospital

Davao City, , Philippines

Site Status

Davao Medical School Foundation

Davao City, , Philippines

Site Status

West Visayas State University Hospital

Iloilo City, , Philippines

Site Status

Jose Reyes Memorial Medical Center

Manila, , Philippines

Site Status

University of Santo Tomas

Manila, , Philippines

Site Status

Philippine General Hospital

Manila, , Philippines

Site Status

National University Hospital

Singapore, Singapore, Singapore

Site Status

National Neuroscience Institute - Tan Tock Seng Campus

Singapore, Singapore, Singapore

Site Status

Singapore General Hospital

Singapore, Singapore, Singapore

Site Status

Changi General Hospital

Singapore, Singapore, Singapore

Site Status

University of Kelaniya

Ragama, , Sri Lanka

Site Status

Chiangmai University Hospital

Muang City, Chiangmai, Thailand

Site Status

King Chulalongkorn Memorial Hospital

Bangkok, , Thailand

Site Status

Prasat Neurological Institute

Bangkok, , Thailand

Site Status

Rajvithee Hospital

Bangkok, , Thailand

Site Status

Thammasart Hospital

Bangkok, , Thailand

Site Status

King Mongkutla Hospital

Bangkok, , Thailand

Site Status

Siriraj Hospital

Bangkok, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong Malaysia Philippines Singapore Sri Lanka Thailand

References

Explore related publications, articles, or registry entries linked to this study.

Young SH, Zhao Y, Koh A, Singh R, Chan BP, Chang HM, Venketasubramanian N, Chen C; CHIMES Investigators. Safety profile of MLC601 (Neuroaid) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine neuroaid efficacy on stroke recovery study. Cerebrovasc Dis. 2010;30(1):1-6. doi: 10.1159/000313398. Epub 2010 Apr 16.

Reference Type BACKGROUND
PMID: 20395679 (View on PubMed)

Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BP, Chan E, Bousser MG, Xuemin S. Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery. Stroke. 2009 Mar;40(3):859-63. doi: 10.1161/STROKEAHA.108.531616. Epub 2009 Jan 22.

Reference Type BACKGROUND
PMID: 19164787 (View on PubMed)

Gan R, Lambert C, Lianting J, Chan ES, Venketasubramanian N, Chen C, Chan BP, Samama MM, Bousser MG. Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients. Cerebrovasc Dis. 2008;25(5):450-6. doi: 10.1159/000126919. Epub 2008 Apr 16.

Reference Type BACKGROUND
PMID: 18417963 (View on PubMed)

Venketasubramanian N, Chen CL, Gan RN, Chan BP, Chang HM, Tan SB, Picard D, Navarro JC, Baroque AC 2nd, Poungvarin N, Donnan GA, Bousser MG; CHIMES Investigators. A double-blind, placebo-controlled, randomized, multicenter study to investigate CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES Study). Int J Stroke. 2009 Feb;4(1):54-60. doi: 10.1111/j.1747-4949.2009.00237.x.

Reference Type BACKGROUND
PMID: 19236501 (View on PubMed)

Chen CLH, Chai JH, Pokharkar YM, Venketasubramanian N. Cost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo - the CHIMES & CHIMES-E studies. BMC Health Serv Res. 2024 Sep 27;24(1):1127. doi: 10.1186/s12913-024-11618-4.

Reference Type DERIVED
PMID: 39334395 (View on PubMed)

Lee CF, Venketasubramanian N, Wong KS, Chen CL; CHIMES Study Investigators. Comparison Between the Original and Shortened Versions of the National Institutes of Health Stroke Scale in Ischemic Stroke Patients of Intermediate Severity. Stroke. 2016 Jan;47(1):236-9. doi: 10.1161/STROKEAHA.115.011657. Epub 2015 Dec 1.

Reference Type DERIVED
PMID: 26628386 (View on PubMed)

Chen CL, Venketasubramanian N, Lee CF, Wong KS, Bousser MG; CHIMES Study Investigators. Effects of MLC601 on early vascular events in patients after stroke: the CHIMES study. Stroke. 2013 Dec;44(12):3580-3. doi: 10.1161/STROKEAHA.113.003226. Epub 2013 Oct 17.

Reference Type DERIVED
PMID: 24135924 (View on PubMed)

Chen CL, Young SH, Gan HH, Singh R, Lao AY, Baroque AC 2nd, Chang HM, Hiyadan JH, Chua CL, Advincula JM, Muengtaweepongsa S, Chan BP, de Silva HA, Towanabut S, Suwanwela NC, Poungvarin N, Chankrachang S, Wong KS, Eow GB, Navarro JC, Venketasubramanian N, Lee CF, Bousser MG; CHIMES Study Investigators. Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study. Stroke. 2013 Aug;44(8):2093-100. doi: 10.1161/STROKEAHA.113.002055. Epub 2013 Jun 18.

Reference Type DERIVED
PMID: 23780952 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SQSTR03 - CHIMES

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Plan of Ischemic Stroke
NCT04953663 UNKNOWN PHASE1/PHASE2